About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Impact of SGLT2 on Glucosuria in HNF1A-MODY | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT05417646

Impact of SGLT2 on Glucosuria in HNF1A-MODY

Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes. The most common cause of MODY is due to mutations in the gene h...

Lead sponsor: Steno Diabetes Center Copenhagen•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Steno Diabetes Center Copenhagen

Collaborators

University of Copenhagen

Participants: Patients with HNF1A-MODY (n=12) and patients with T2D (n=12)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥18 years
•HNF1A-MODY verified by genetic testing (only patients with HNF1A-MODY)
•Type 2 diabetes diagnosis according to World Health Organization (only patients with type 2 diabetes)
•Treatment with diet and/or a glucose-lowering drug (only patients with HNF1A-MODY)
•Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)
•Informed consent

Exclusion Criteria

•Nephropathy (estimated GFR \<60 ml/min/1.73m2 and/or albuminuria)
•Known significant liver disease and/or plasma alanine aminotransferase (ALT) and/or plasma aspartate aminotransferase (AST) above 2 × normal values)
•Pregnancy or breastfeeding
•Treatment with SGLT2 inhibitor
•Fasting plasma glucose \> 10 mmol/l
•Family history of HNF1A-MODY (only patients with type 2 diabetes)

Related studies

Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes

NCT07659535 · Type 2 Diabetes

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147 · Type 1 Diabetes (T1D), Type 2 Diabetes, and more

RECRUITINGPhase 3

Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients

NCT07581145 · Foot Ulcer Due to Type 2 Diabetes Mellitus

Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD

NCT07187830 · Chronic Kidney Disease in Type 2 Diabetes, Obesity & Overweight

LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes

NCT06319716 · Type 2 Diabetes

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 27, 2023Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment21

Start dateJun 2022

Last updatedJul 27, 2023

Condition

Maturity-Onset Diabetes of the Young, Type 3 Type 2 Diabetes

Locations shown

Steno Diabetes Center Copenhagen

Herlev

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 27, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions